The role of the endocannabinoid system in liver diseases
The role of the endocannabinoid system in liver diseases
复制标题
DOI：
10.1016/j.beem.2008.10.009
复制
发表时间：
2009-02-01
影响因子：
7.4
通讯作者：
Bernardi, Mauro
中科院分区：
文献类型：
--
作者：
Caraceni, Paolo;Domenicali, Marco;Bernardi, Mauro
内源性大麻素（Endogenous cannabinoids，ECs）是一种广泛存在的脂质信号分子，主要由特异性受体CB1和CB2介导。在过去的十年中，相当多的研究表明，EC及其受体在肝脏疾病的病理生理学中起着重要作用。EC系统在慢性肝病期间强烈上调。到目前为止，它已被牵连在与肥胖，酒精滥用和丙型肝炎相关的脂肪肝疾病的发病机制中，在纤维化向肝硬化的进展中，以及在门静脉高压症，高动力循环综合征及其并发症，以及急性心肌病的发展中。此外。EC系统可通过调节细胞损伤和炎症反应的机制参与急性肝损伤的发病机制。因此，靶向CB1和CB2受体代表了治疗肝脏疾病的潜在治疗目标。(C)2008爱思唯尔有限公司保留所有权利。
Endogenous cannabinoids (ECs) are ubiquitous lipid signaling molecules provided by a number of central and peripheral effects, which are mediated mainly by the specific receptors CB1 and CB2. In the last decade a considerable number of studies has shown that ECs and their receptors play an important role in the pathophysiology of liver diseases. The EC system is strongly up-regulated during chronic liver diseases. Until now it has been implicated in the pathogenesis of fatty liver disease associated with obesity, alcohol abuse, and hepatitis C, in the Progression of fibrosis to Cirrhosis, and in the development of portal hypertension, hyperdynamic circulatory syndrome and its complications, and cirrhotic cardiomyopathy. Furthermore. the EC system can participate in the pathogenesis of acute liver injury by modulating the mechanisms responsible for cell injury and inflammatory response. Thus, targeting the CBI and CB2 receptors represents a potential therapeutic goal for the treatment of liver diseases. (C) 2008 Elsevier Ltd. All rights reserved.